Treatment of Unresectable, Locally Advanced Pancreatic Adenocarcinoma with Combined Radiochemotherapy with 5-Fluorouracil and Cisplatin, Pancreas, vol.25, issue.4, pp.360-365, 2002. ,
DOI : 10.1097/00006676-200211000-00007
Pancreatic Cancer Research Matures, JNCI Journal of the National Cancer Institute, vol.99, issue.19, pp.1432-1434, 2007. ,
DOI : 10.1093/jnci/djm180
URL : http://jnci.oxfordjournals.org/cgi/content/short/99/19/1432
Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses, Science, vol.321, issue.5897, pp.1801-1806, 2008. ,
DOI : 10.1126/science.1164368
Pancreatic cancer: molecular pathogenesis and new therapeutic targets, Nature Reviews Gastroenterology & Hepatology, vol.3, issue.7, pp.412-422, 2009. ,
DOI : 10.1038/nrgastro.2009.89
Monoclonal antibodies in the treatment of pancreatic cancer, Immunotherapy, vol.1, issue.2, pp.223-239, 2009. ,
DOI : 10.2217/1750743X.1.2.223
In vivo Therapeutic Synergism of Anti-Epidermal Growth Factor Receptor and Anti-HER2 Monoclonal Antibodies against Pancreatic Carcinomas, Clinical Cancer Research, vol.13, issue.11, pp.3356-62, 2007. ,
DOI : 10.1158/1078-0432.CCR-06-2302
URL : https://hal.archives-ouvertes.fr/inserm-00153693
Coexpression of epidermal growth factor receptor and ligands in human pancreatic cancer is associated with enhanced tumor aggressiveness, Anticancer Res, vol.13, pp.565-569, 1993. ,
Overexpression of the HER-2/ neu Oncogene in Pancreatic Adenocarcinoma, American Journal of Clinical Oncology, vol.24, issue.5, pp.496-499, 2001. ,
DOI : 10.1097/00000421-200110000-00016
Untangling the ErbB signalling network, Nature Reviews Molecular Cell Biology, vol.2, issue.2, pp.127-137, 2001. ,
DOI : 10.1038/35052073
Erlotinib Plus Gemcitabine Compared With Gemcitabine Alone in Patients With Advanced Pancreatic Cancer: A Phase III Trial of the National Cancer Institute of Canada Clinical Trials Group, Journal of Clinical Oncology, vol.25, issue.15, pp.1960-1966, 2007. ,
DOI : 10.1200/JCO.2006.07.9525
Lapatinib/Gemcitabine and Lapatinib/Gemcitabine/Oxaliplatin, American Journal of Clinical Oncology, vol.31, issue.2, pp.140-144, 2008. ,
DOI : 10.1097/COC.0b013e318145b9a5
Combined cetuximab and trastuzumab are superior to gemcitabine in the treatment of human pancreatic carcinoma xenografts, Annals of Oncology, vol.21, issue.1, pp.98-103, 2010. ,
DOI : 10.1093/annonc/mdp496
URL : https://hal.archives-ouvertes.fr/inserm-00431431
MHC Class I-Related Chain A Conjugated to Antitumor Antibodies Can Sensitize Tumor Cells to Specific Lysis by Natural Killer Cells, Clinical Cancer Research, vol.11, issue.20, pp.7516-7538, 2005. ,
DOI : 10.1158/1078-0432.CCR-05-0872
Time-resolved Fluorescence Resonance Energy Transfer (TR-FRET) to Analyze the Disruption of EGFR/HER2 Dimers: A NEW METHOD TO EVALUATE THE EFFICIENCY OF TARGETED THERAPY USING MONOCLONAL ANTIBODIES, Journal of Biological Chemistry, vol.286, issue.13, pp.11337-11345, 2011. ,
DOI : 10.1074/jbc.M111.223503
URL : https://hal.archives-ouvertes.fr/inserm-00576598
Direct comparison of a radioiodinated intact chimeric anti-CEA MAb with its F(ab')2 fragment in nude mice bearing different human colon cancer xenografts, British Journal of Cancer, vol.68, issue.4, pp.684-90, 1993. ,
DOI : 10.1038/bjc.1993.410
Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets, Nat Med, vol.6, pp.443-446, 2000. ,
FcRn: the neonatal Fc receptor comes of age, Nature Reviews Immunology, vol.100, issue.9, pp.715-740, 2007. ,
DOI : 10.1038/nri2155
Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer, New England Journal of Medicine, vol.359, issue.17, pp.1757-1765, 2008. ,
DOI : 10.1056/NEJMoa0804385
Molecular predictors of outcome in a phase 3 study of gemcitabine and erlotinib therapy in patients with advanced pancreatic cancer, Cancer, vol.62, issue.suppl 4, pp.5599-5607, 2010. ,
DOI : 10.1002/cncr.25393
Cooperative inhibitory effect of ZD1839 (Iressa) in combination with trastuzumab (Herceptin) on human breast cancer cell growth, Annals of Oncology, vol.13, issue.1, pp.65-72, 2002. ,
DOI : 10.1093/annonc/mdf020
Dual-Agent Molecular Targeting of the Epidermal Growth Factor Receptor (EGFR): Combining Anti-EGFR Antibody with Tyrosine Kinase Inhibitor, Cancer Research, vol.64, issue.15, pp.5355-62, 2004. ,
DOI : 10.1158/0008-5472.CAN-04-0562
A quantitative analysis of kinase inhibitor selectivity, Nature Biotechnology, vol.50, issue.1, pp.127-159, 2008. ,
DOI : 10.1038/nbt1358
ErbB3 expression and dimerization with EGFR influence pancreatic cancer cell sensitivity to erlotinib, Cancer Biology & Therapy, vol.6, issue.4, pp.548-554, 2007. ,
DOI : 10.4161/cbt.6.4.3849
Inactivation of Akt by the epidermal growth factor receptor inhibitor erlotinib is mediated by HER-3 in pancreatic and colorectal tumor cell lines and contributes to erlotinib sensitivity, Molecular Cancer Therapeutics, vol.5, issue.8, pp.2051-2059, 2006. ,
DOI : 10.1158/1535-7163.MCT-06-0007
evidence that a combination of lapatinib plus S-1 is a promising treatment for pancreatic cancer, Cancer Science, vol.355, issue.2, pp.468-473, 2010. ,
DOI : 10.1111/j.1349-7006.2009.01405.x
Radiosensitization of Epidermal Growth Factor Receptor/HER2-Positive Pancreatic Cancer Is Mediated by Inhibition of Akt Independent of Ras Mutational Status, Clinical Cancer Research, vol.16, issue.3, pp.912-923, 2010. ,
DOI : 10.1158/1078-0432.CCR-09-1324
, GW572016) in an expanded panel of human normal and tumour cell lines, Cell Proliferation, vol.23, issue.2, pp.580-594, 2007. ,
DOI : 10.1023/A:1006111117877
Lapatinib, a Dual EGFR and HER2 Kinase Inhibitor, Selectively Inhibits HER2-Amplified Human Gastric Cancer Cells and is Synergistic with Trastuzumab In vitro and In vivo, Clinical Cancer Research, vol.16, issue.5, pp.1509-1519, 2010. ,
DOI : 10.1158/1078-0432.CCR-09-1112
Lapatinib, a HER2 tyrosine kinase inhibitor, induces stabilization and accumulation of HER2 and potentiates trastuzumab-dependent cell cytotoxicity, Oncogene, vol.171, issue.6, pp.803-814, 2009. ,
DOI : 10.1107/S0907444993000423
Persistent elimination of ErbB-2/HER2-overexpressing tumors using combinations of monoclonal antibodies: Relevance of receptor endocytosis, Proceedings of the National Academy of Sciences, vol.106, issue.9, pp.3294-3299, 2009. ,
DOI : 10.1073/pnas.0812059106
Oncogenic KRAS Activates Hedgehog Signaling Pathway in Pancreatic Cancer Cells, Journal of Biological Chemistry, vol.282, issue.19, pp.14048-14055, 2007. ,
DOI : 10.1074/jbc.M611089200
Multicenter Phase II Study of the Oral MEK Inhibitor, CI-1040, in Patients With Advanced Non-Small-Cell Lung, Breast, Colon, and Pancreatic Cancer, Journal of Clinical Oncology, vol.22, issue.22, pp.4456-4462, 2004. ,
DOI : 10.1200/JCO.2004.01.185
Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer, Molecular Cancer Therapeutics, vol.6, issue.3, pp.1079-1088, 2007. ,
DOI : 10.1158/1535-7163.MCT-06-0448
Combination of cetuximab with chemoradiation, trastuzumab or MAPK inhibitors: mechanisms of sensitisation of cervical cancer cells, British Journal of Cancer, vol.3, issue.5, pp.782-791, 2009. ,
DOI : 10.1038/onc.2008.19
Trastuzumab Has Preferential Activity against Breast Cancers Driven by HER2 Homodimers, Cancer Research, vol.71, issue.5, pp.1871-1882, 2011. ,
DOI : 10.1158/0008-5472.CAN-10-1872
Direct visualization of the phosphorylated epidermal growth factor receptor during its internalization in A-431 cells, The Journal of Cell Biology, vol.105, issue.6, pp.2751-2762, 1987. ,
DOI : 10.1083/jcb.105.6.2751
All ErbB receptors other than the epidermal growth factor receptor are endocytosis impaired, J Biol Chem, vol.271, pp.5251-5257, 1996. ,
Endocytosis Deficiency of Epidermal Growth Factor (EGF) Receptor-ErbB2 Heterodimers in Response to EGF Stimulation, Molecular Biology of the Cell, vol.10, issue.5, pp.1621-1636, 1999. ,
DOI : 10.1091/mbc.10.5.1621